Results 201 to 210 of about 9,104 (252)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

Pharmacological treatment with a GABA(A) receptor modulator and a selective serotonin reuptake inhibitor as a mitigation strategy against aircraft noise‐induced cardiovascular and neuronal damage

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Noise pollution, particularly by aircraft, is a significant risk factor for cardiovascular disease. Aircraft noise activates stress response pathways in the brain, via the amygdala, the sympathetic nervous system and the hypothalamic–pituitary–adrenal axis.
Ivana Kuntić, Marin Kuntić, Jiayin Zheng, Leonardo Nardi, Matthias Oelze, Arijan Valar, Dominika Mihaliková, Lea Strohm, Hans‐Georg Buchholz, Nicole Bausbacher, Simon Lange, Henning Ubbens, Qi Tang, Liyu Zhang, Guilherme Horta, Paul Stamm, Omar Hahad, Axel Methner, Sebastian Steven, Huige Li, Mathias Schreckenberger, Dilja Krueger‐Burg, Adrian Gericke, Michael J. Schmeisser, Thomas Münzel, Andreas Daiber   +25 more
wiley   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen, Nils Johan Fredriksson, Michael Andresen, Jon Jonasson, Malin Lindqvist Appell, Henrik Gréen   +5 more
wiley   +1 more source

Identification, reliability, and validity of drug–drug interaction checkers in chronic diseases: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Drug–drug interactions (DDIs) pose major risks in chronic disease management where polypharmacy is common. Although digital DDI tools are used widely to aid healthcare professionals, tools rely on theoretical interactions. This limitation questions their reliability and validity for clinical relevancy.
Brayden Ng Gibson, Sri Chodapuneedi, Huan Yee Koh, Sugandha Gupta, Danijela Gasevic, Anna Yuanyuan Wang, Catia Marzolini, Saye Khoo, Lorena Romero, Lachlan Dalli, Jack Janetzki, Harvey Jia Wei Koh, Stella Talic   +12 more
wiley   +1 more source

Reading and relating with Frieda Fromm‐Reichmann and Joanne Greenberg

Critical Quarterly, EarlyView.
Joshua Pugh
wiley   +1 more source

Novel psychoactive substances of interest for psychiatry [PDF]

World Psychiatry, 2015
Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a range of prescribed medications, psychoactive plants/herbs, and a large series of performance and ...
Fabrizio Schifano, Laura Orsolini, John M Corkery   +2 more
exaly   +3 more sources

Novel psychoactive substances: the pharmacology of stimulants and hallucinogens [PDF]

Expert Review of Clinical Pharmacology, 2016
There are increasing levels of concern relating to the rapidly evolving novel psychoactive substances/NPS and web markets' scenarios. The paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens.
Fabrizio Schifano, Laura Orsolini, John M Corkery   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Novel Psychoactive Substances and Trends of Abuse

Critical Care Nursing Quarterly, 2017
The purpose of this paper is to review the most common and quickest growing classes of novel, or new, psychoactive substances. Abuse of novel psychoactive substances continues to increase, resulting in subsequent increases in hospitalizations. Furthermore, the chemical structures are ever-changing and substances are increasing in potency. Reviewing the
Jessica V, Rivera, Emily Green, Vance, William F, Rushton, Justin K, Arnold   +3 more
openaire   +2 more sources